Email this article 
Optimization of the systemic therapy stage in the management of patients with anaplastic thyroid cancer: the experience of one center
- Authors: Dzhelialov E.S.1, Sleptsov I.V.1, Chernikov R.A.1, Timofeeva N.I.1, Sereda O.A.1, Mikheeva Y.V.2, Zulkarnaev A.B.3, Shostka K.G.1, Belousov A.M.1, Orlova R.V.1,4
-
Affiliations:
- N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University
- National Medical Research Centre “Treatment and Rehabilitation Centre”, Ministry of Health of Russia
- M.F. Vladimirsky Moscow Regional Research Clinical Institute
- City Clinical Oncology Dispensary
- Issue: Vol 15, No 4 (2025)
- Pages: 52-59
- Section: DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS
- Published: 18.03.2026
- URL: https://ogsh.abvpress.ru/jour/article/view/1084
- DOI: https://doi.org/10.17650/2222-1468-2025-15-4-52-59
- ID: 1084
Cite item
Full Text
Abstract
Introduction. Anaplastic thyroid cancer is a rare and extremely aggressive disease characterized by unfavorable prognosis. Improvement of systemic therapy allowed to treat this pathology, however its efficacy is limited.
Aim. To evaluate in real clinical practice efficacy of various systemic therapy regimens in patients with anaplastic thyroid cancer.
Materials and methods. A retrospective study of patients who received systemic therapy between 2019 and 2024 in N. I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University was performed with assessment of progression-free survival, overall survival, and objective response rate.
Results. Data on efficacy of 4 systemic therapy regimens were obtained: dabrafenib+ trametinib (n = 41; with BRAF gene mutation 41 (100 %) cases, without previous therapy 36 (87.8 %) cases), paclitaxel + carboplatin (n = 55; with BRAF gene mutation 14 (25.5 %) cases, without без previous therapy 44 (80 %) cases); doxorubicin (n = 17; with BRAF gene mutation 6 (35.3 %) cases, with previous therapy 17 (100 %) cases); pembrolizumab + lenvatinib (n = 18; with BRAF gene mutation 5 (27.8 %) cases, without previous therapy 11 (61.1 %) cases). Median progression-free survival in the dabrafenib + trametinib group was 163 days (95 % confidence interval 93–402), in the paclitaxel + carboplatin group 71 days, in the doxorubicin group 42 days, not reached in the pembrolizumab + lenvatinib group. Objective response rate for dabrafenib + trametinib therapy was 65.9 %, for paclitaxel + carboplatin 16.4 %, for doxorubicin 0 %, for pembrolizumab + lenvatinib 50 %. Median overall survival of patients with BRAF gene mutation was 299 days, of patients without it 156 days. One- and 2-year overall survival in these groups was 41.3 and 32.5 % versus 21.4 and 16.1 %, respectively.
Conclusion. Immune therapy is a promising approach to treatment of anaplastic thyroid cancer but observation of these patients continues. Further search for new treatments for this pathology is necessary.
About the authors
E. S. Dzhelialov
N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University
Author for correspondence.
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0002-2571-243X
Russian Federation, 154 Fontanka River Emb., Saint Petersburg 190103
I. V. Sleptsov
N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0002-1903-5081
Russian Federation, 154 Fontanka River Emb., Saint Petersburg 190103
R. A. Chernikov
N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0002-3001-664X
Russian Federation, 154 Fontanka River Emb., Saint Petersburg 190103
N. I. Timofeeva
N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0001-6594-8845
Russian Federation, 154 Fontanka River Emb., Saint Petersburg 190103
O. A. Sereda
N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0001-7553-2026
Russian Federation, 154 Fontanka River Emb., Saint Petersburg 190103
Yu. V. Mikheeva
National Medical Research Centre “Treatment and Rehabilitation Centre”, Ministry of Health of Russia
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0009-0009-2644-3102
Russian Federation, 3 Ivankovskoe Shosse, Moscow 125367
A. B. Zulkarnaev
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0001-5405-7887
Russian Federation, 61 / 2 Shchepkina St., Moscow 129110
K. G. Shostka
N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0003-2654-1190
Russian Federation, 154 Fontanka River Emb., Saint Petersburg 190103
A. M. Belousov
N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0002-2274-8170
Russian Federation, 154 Fontanka River Emb., Saint Petersburg 190103
R. V. Orlova
N.I. Pirogova Clinic of High Medical Technologies, Saint Petersburg State University; City Clinical Oncology Dispensary
Email: ernest.dzhelialov@gmail.com
ORCID iD: 0000-0003-4447-9458
Russian Federation, 154 Fontanka River Emb., Saint Petersburg 190103; 56 Veteranov Prospekt, Saint Petersburg 192288
References
- Jannin A., Escande A., Al Ghuzlan A. et al. Anaplastic thyroid carcinoma: an update. Cancers (Basel) 2022;14(4):1061. doi: 10.3390/cancers14041061
- Smallridge R.C., Copland J.A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 2010;22(6):486–97. doi: 10.1016/j.clon.2010.03.013
- Bible K.C., Kebebew E., Brierley J. et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 2021;31(3):337–86. doi: 10.1089/thy.2020.0944
- Subbiah V., Kreitman R.J., Wainberg Z.A. et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022;33(4):406–15. doi: 10.1016/j.annonc.2021.12.014
- Mavroeidis L., Napolitano A., Huang P., Jones R.L. Real-world evidence for ultra rare cancers. Rare Tumors 2024;16:20363613241234207. doi: 10.1177/20363613241234207
- Schott A.F., Welch J.J., Verschraegen C.F., Kurzrock R. The National Clinical Trials Network: conducting successful clinical trials of new therapies for rare cancers. Semin Oncol 2015;42(5):731–9. doi: 10.1053/j.seminoncol.2015.07.010
- Jenkins D.A., Hussein H., Martina R. et al. Methods for the inclusion of real-world evidence in network meta-analysis. BMC Med Res Methodol 2021;21(1):207. doi: 10.1186/s12874-021-01399-3
- Sosa J.A., Elisei R., Jarzab B. et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014;24(2):232–40. doi: 10.1089/thy.2013.0078
- Onoda N., Sugino K., Higashiyama T. et al. The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid 2016;26(9):1293–9. doi: 10.1089/thy.2016.0072
- Shimaoka K., Schoenfeld D.A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155–60. doi: 10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e
Supplementary files
